Document is current
Any future updates will be listed below
-
Authors
Gallon, Richard https://orcid.org/0000-0002-5395-0099
McCormick, Liam https://orcid.org/0000-0001-9557-9403
Saetta, Angelica https://orcid.org/0000-0002-4862-3413
Albuquerque, Cristina https://orcid.org/0000-0002-9707-0317
Butler, Samantha
Cranston, Treena
Field, Joanne
McAnulty, Ciaron
Silva, Patrícia https://orcid.org/0000-0002-3713-8770
Cheetham, Melanie
Sheils, Katie https://orcid.org/0000-0002-1649-1495
Burghel, George J. https://orcid.org/0000-0001-9360-8194
- License Information
-
More Information
Article History
Received: 16 December 2024
Revised: 24 June 2025
Accepted: 8 July 2025
First Online: 20 August 2025
Change Date: 16 October 2025
Change Type: Update
Change Details: In the Introduction, in the sentence “These guidelines cover MSI caused by deficiency of the four core MMR proteins MLH1, MSH2, MSH6, and PMS2, whilst elevated microsatellite alterations at selected tetranucleotide repeats (which have been associated with MSH3 deficiency) are not considered due to unclear clinical relevance.”, the verbs “have been associated” and “are not considered” have been corrected to “has been associated” and “is not considered”.
Competing interests
: RG is a co-inventor on patents covering panels of microsatellite instability markers: WO/2021/019197 (published February 4, 2021) and GB2114136.1 (filed October 1, 2021). The other authors declare no competing interests.
: Ethical approval was not needed for the literature review and formulation of these guidelines.
